Trial Profile
A Phase II Randomised, Placebo-controlled, Multicentre Study in Prostate Cancer Patients With Painful Bone Metastases to Evaluate the Efficacy of Repeated Radium-223 Injections.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Bayer
- 19 Feb 2011 Results were presented in combination with results from the BC1-04 study (59636) at the 2011 Genitourinary Cancers Symposium.
- 24 Sep 2010 New trial record